Register now for MPE’s webinar on Evidence-Based Patient AdvocacyMPE, Patient evidenceOctober 19, 2020
The FDA approves belantamab mafodotin for relapsed or refractory myelomaAccess, MyelomaAugust 6, 2020
ASCO and EHA highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, Myeloma, VideosJuly 20, 2020
EHA 2020 – Subcutaneous daratumumab shows improved clinical outcomes in AL amyloidosisAL amyloidosisJune 14, 2020
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, MyelomaMay 14, 2020
